410 related articles for article (PubMed ID: 29361332)
21. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
22. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy.
Pfaar O; Urry Z; Robinson DS; Sager A; Richards D; Hawrylowicz CM; Bräutigam M; Klimek L
Allergy; 2012 Feb; 67(2):272-9. PubMed ID: 22107266
[TBL] [Abstract][Full Text] [Related]
23. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma.
Pfaar O; Bachert C; Kuna P; Panzner P; Džupinová M; Klimek L; van Nimwegen MJ; Boot JD; Yu D; Opstelten DJE; de Kam PJ
J Allergy Clin Immunol; 2019 Mar; 143(3):970-977. PubMed ID: 30508538
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial.
Pfaar O; Klimek L
Ann Allergy Asthma Immunol; 2008 Mar; 100(3):256-63. PubMed ID: 18426146
[TBL] [Abstract][Full Text] [Related]
25. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
26. Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells.
Rauber MM; Möbs C; Campana R; Henning R; Schulze-Dasbeck M; Greene B; Focke-Tejkl M; Weber M; Valenta R; Pfützner W
Allergy; 2020 Feb; 75(2):450-453. PubMed ID: 31330050
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.
Worm M; Rak S; Samoliński B; Antila J; Höiby AS; Kruse B; Lipiec A; Rudert M; Valovirta E
Clin Exp Allergy; 2019 Apr; 49(4):516-525. PubMed ID: 30570787
[TBL] [Abstract][Full Text] [Related]
28. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol.
Klimek L; Uhlig J; Mösges R; Rettig K; Pfaar O
Allergy; 2014 Dec; 69(12):1629-38. PubMed ID: 25130503
[TBL] [Abstract][Full Text] [Related]
29. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis.
Zenner HP; Baumgarten C; Rasp G; Fuchs T; Kunkel G; Hauswald B; Ring J; Effendy I; Behrendt W; Frosch PJ; Przybilla B; Brunner FX; Merk HF; Kapp A; Schnitker J; Wolf H
J Allergy Clin Immunol; 1997 Jul; 100(1):23-9. PubMed ID: 9257783
[TBL] [Abstract][Full Text] [Related]
30. Allergen-specific immunotherapy with recombinant grass pollen allergens.
Jutel M; Jaeger L; Suck R; Meyer H; Fiebig H; Cromwell O
J Allergy Clin Immunol; 2005 Sep; 116(3):608-13. PubMed ID: 16159631
[TBL] [Abstract][Full Text] [Related]
31. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.
Sola Martínez FJ; Barranco Jiménez RM; Martín García C; Senent Sánchez C; Blanco Guerra C; Fernández-Rivas M; Vega Castro A; Dávila González I; Carbonell Martínez A; Panizo Bravo C; Gómez Torrijos E; Rodríguez Gil D; Palacios Peláez R
Clin Exp Allergy; 2020 Dec; 50(12):1352-1361. PubMed ID: 32946612
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study.
Bufe A; Ziegler-Kirbach E; Stoeckmann E; Heidemann P; Gehlhar K; Holland-Letz T; Braun W
Allergy; 2004 May; 59(5):498-504. PubMed ID: 15080830
[TBL] [Abstract][Full Text] [Related]
33. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
34. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.
Durham SR; Emminger W; Kapp A; de Monchy JG; Rak S; Scadding GK; Wurtzen PA; Andersen JS; Tholstrup B; Riis B; Dahl R
J Allergy Clin Immunol; 2012 Mar; 129(3):717-725.e5. PubMed ID: 22285278
[TBL] [Abstract][Full Text] [Related]
35. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
Winther L; Malling HJ; Mosbech H
Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
[TBL] [Abstract][Full Text] [Related]
36. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
37. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
38. Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial.
Caffarelli C; Sensi LG; Marcucci F; Cavagni G
Allergy; 2000 Dec; 55(12):1142-7. PubMed ID: 11117271
[TBL] [Abstract][Full Text] [Related]
39. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
40. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
